Washington Oregon Biotech Networks’ Post

📢📰 Manas AI Secures $24.6M in Seed Funding 🗞️ 🔔 ➡️ LinkedIn founder Reid Hoffman and renowned cancer researcher Siddhartha Mukherjee have co-founded Manas AI, an AI-powered drug discovery startup that has raised $24.6 million in seed funding. The company will initially focus on developing novel treatments for breast cancer, prostate cancer, and lymphoma. Although this amount is relatively modest compared to other AI drug discovery startups, such as Xaira's $1 billion initial funding and Treeline Biosciences' $422 million, Manas AI's approach is noteworthy. 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 1️⃣ Manas AI will leverage AI to design molecules, which will then be tested in a wet lab, marking a significant step in the drug discovery process 🧬 2️⃣ The startup will utilize Microsoft's Azure cloud computing platform and deep domain knowledge in AI to develop innovative medicines 🌐 3️⃣ Reid Hoffman's connection to Microsoft, which acquired LinkedIn in 2016, may play a crucial role in Manas AI's success 📈 4️⃣ The use of AI in drug discovery has the potential to revolutionize the pharmaceutical industry, enabling faster and more efficient development of novel treatments 🌟 5️⃣ Manas AI's focus on breast cancer, prostate cancer, and lymphoma highlights the urgent need for innovative solutions in these areas 🎗 6️⃣ The relatively modest funding amount may indicate a more measured approach to growth, allowing Manas AI to focus on developing a robust platform and pipeline 📊 #ArtificialIntelligence #DrugDiscovery #HealthcareInnovation #StartupFunding #PharmaceuticalIndustry Reference [https://lnkd.in/ggqqqy8H] 🔄 Share 👍 React 🌐 Visit aravind-r.com [www.aravind-r.com] Found this useful?, Share your comments below 👇

2025 is starting strong for STL! St. Louis startups are making waves with Geneoscopy raising $105M for its at-home colorectal cancer test, Arch Grants awarding $300K to grow local businesses, and BioSTL's NEURO360 vying for a $160M grant to advance the region's neuroscience industry. #STLMade St. Louis-based cancer test firm closes $105M funding round #stlmade startup @GeneoscopyCo has raised $105M in Series C funding to support the commercial launch of its ColoSense at-home screening test for colorectal cancer. More: https://lnkd.in/gXjVBR5n Bathroom ads, a sales system and medical study tool get $300K in Arch Grants funding Three #stlmade startups have been awarded a total of $300K in Growth Grants from @ArchGrants to help grow their businesses. The Growth Grants program provides follow-up resources to Arch Grant companies that have created jobs and expanded operations in St. Louis. More: https://lnkd.in/gG-N4kE3 BioSTL to 'supercharge' St. Louis neuroscience industry Startup accelerator @BioSTL’s NEURO360 coalition was recently named a finalist in @NSF’s Regional Innovation Engines Program. If chosen, the organization would use the $160M in grant funding to supercharge the region’s neuroscience industry. More: https://lnkd.in/g58txRaM

Hitesh Goswami and Kshitij Rishi are on a mission to transform 4baseCare into India’s leading precision oncology company, and their journey is nothing short of remarkable. Precision oncology, at its core, offers hope where traditional cancer treatments often fall short, by tailoring therapies to the unique genetic profile of each patient’s cancer. Their breakthrough work not only improves treatment outcomes but also significantly reduces costs and turnaround times, making advanced cancer care more accessible to millions of Indians. With cancer being among the leading causes of death in the country (second leading in urban India for adults, and the fourth leading cause in rural areas), this work is critical. Today, over 350 of India’s top oncologists rely on 4baseCare's innovative tests to provide targeted treatments that can make a real difference in patient survival and quality of life. The road hasn’t been easy. Hitesh, Kshitij, and their dedicated team have faced immense challenges, yet their resilience and commitment have only strengthened their resolve. I have no doubt that, in the years to come, their contributions will be recognised as pivotal in improving patient outcomes across Asia. A special shoutout to our co-investors, Mount Judi Ventures and Season Two Ventures, whose unwavering support has been crucial during the toughest times. And a warm welcome to Ganapathy Subramaniam, Mathew Cyriac, and the Yali Capital. Your expertise will undoubtedly help 4baseCare overcome every obstacle and achieve its audacious goals. Sheetal Bahl I Ashita Gupta I Dilsher Dhupia I Merak Ventures I growX ventures

Biotech startup ExSURE PVT. LTD. raises Rs 3-Cr in seed round Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure focuses on reducing anti-cancer drug’s side effects and toxicity using its patented exosomal drug delivery platform. This platform targets both cancer and cancer stem cells, aiming to minimize chemotherapy’s toxic effects and reduce the likelihood of cancer relapse, ultimately improving the quality of life for cancer patients. #BiotechIndia #CancerTreatment #StartupFunding #Biotech #stemcells

WOBN Trending News: Seattle Immunotherapy Startup Umoja Biopharma Raises $100M https://lnkd.in/g95UEWtT Another Seattle-area health startup is raising a big new round of funding. Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR T-cell immunotherapy treatments for cancer. [...]

💵 Funding News: 🗓️ News Month: October, 2024 🎯 Revolutionizing Cancer Treatment: Kivu Bioscience Secures $92M in Series A! 💊 San Francisco-based Kivu Biosciences is advancing next-generation antibody-drug conjugates (ADCs) in oncology. 🚀 What This Funding Means: 🔸Backed by Industry Leaders💡: Novo Holdings led the round with participation from Gimv, Red Tree Venture Capital, HealthCap as well as existing investors BGV (BioGeneration Ventures), M Ventures , and Brabantse Ontwikkelings Maatschappij (BOM). 🔹Accelerating Clinical Trials 🧪: Funds will drive clinical development of multiple ADC programs. 🔸Cutting-Edge Technology 🔬: Proprietary linker-payload tech ensures safer, more effective treatments. Why It Matters: Led by President and COO ,Mohit Trikha, Kivu Biosciences is minimizing off-target effects in cancer therapies, delivering better outcomes for patients. Two lead candidates are on track to enter clinical trials in 2025. The future of oncology is here, and it’s transformative. 🌟 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs ♻️ Repost if you think this insight is worth sharing!

ExSURE PVT. LTD., an innovative biotech startup revolutionizing cancer treatment, has successfully raised Rs 3 crore in a seed funding round led by Unicorn India Ventures! Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is focused on reducing the side effects and toxicity of anti-cancer drugs using a cutting-edge exosome-based drug delivery platform. This technology targets both cancer and cancer stem cells, aiming to improve the quality of life for patients and minimize chemotherapy’s toxic effects. The fresh funds will help Exsure complete its non-clinical studies, expand its global reach, and support the promotion of key products like Exosure, Leucosure, PlantExosure, and Dr. Berries. With fivefold growth in the past fiscal year, Exsure is on track to service 50+ clients this year and has been selected for the OIST Innovation Accelerator Program in Japan! The Indian biotech sector is on track to reach $150 billion by 2025, and Exsure is well-positioned to be a major player in this booming industry. Read More: https://lnkd.in/gCXU69hq #Exsure #SeedFunding #Biotech #CancerTreatment #ExosomeTechnology #Innovation #HealthTech #Startups #Biotechnology #CancerResearch #R&D #GlobalExpansion #OISTInnovationAccelerator #UnicornIndiaVentures

Last quarter was the best fundraising quarter for biotech startups in about two years, hopefully indicating that industry downturn will soon be a thing of the past! Demonstrating this, last week Pathios Therapeutics and Stuart Hughes secured $25M in Series B Financing to advance their unique immunotherapy approach into Clinic 💰 Pathios Therapeutics is a biotech startup whose approach targets the acidic microenvironment. This acidic environment triggers immune cell signaling, via receptors such as GPR65, and ultimately leads to disease progression. Pathios aims to reverse immune alterations by blocking GPR65 signaling which will potentially improve cancer treatment outcomes, especially for patients unresponsive to current therapies. How exciting to see these startups acquiring further funding! 👏 Which companies do you think have the potential to secure funding? #biotech #pathiostherapeutics #immunotherapy #recruiter #researchanddevelopment

#𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐒𝐭𝐨𝐫𝐲𝟑 Continuing the series of spotlighting o2h Kickstarter winners and celebrating their success stories, this time we are excited to introduce our latest winner, Palm Therapeutics. Palm Therapeutics, a #USA-based biotech startup in cancer research, is redefining the field with its development of depalmitoylating molecules (DPALMs) that target protein palmitoylation - a novel approach to inhibiting protein function. Their NRas-targeted DPALMs have shown significant in vitro and in vivo efficacy in NRas-driven melanoma models. Palm Tx’s has also been recognised as a 2024 cool company by Connect. Read here - https://lnkd.in/gcYyQ8wu Their innovative work is positively impacting cancer research, and we are proud to support their journey towards finding novel drugs for unmet patient needs and ultimately improving human health! o2h Discovery has supported many early-stage biotech startups through the Kickstarter Award. Our latest edition, 𝐨𝟐𝐡 𝐊𝐢𝐜𝐤𝐬𝐭𝐚𝐫𝐭𝐞𝐫: 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 is 𝐧𝐨𝐰 𝐥𝐢𝐯𝐞, which is exclusively designed to provide scientific expertise to USA-based biotech startups. If this sounds like a fit for you and you’d like to avail the benefits, below is the link to register your interest and be a part of our success stories. 👉 https://lnkd.in/dAxrjKjn Andrew Rudd Digital Elevator Altitude Marketing Samba Scientific Alchemist Accelerator BioGenerator Ventures BioMotiv #Biotech #Proteomics #DrugDiscovery #Oncology #Innovation #Testimonial #o2hKickstarter #ClientStory #SeedingNewIdeas #CancerResearch

St. Louis-based cancer test firm closes $105M funding round #stlmade startup @GeneoscopyCo has raised $105M in Series C funding to support the commercial launch of its ColoSense at-home screening test for colorectal cancer. More: https://lnkd.in/gxScb627 Bathroom ads, a sales system and medical study tool get $300K in Arch Grants funding Three #stlmade startups have been awarded a total of $300K in Growth Grants from @ArchGrants to help grow their businesses. The Growth Grants program provides follow-up resources to Arch Grant companies that have created jobs and expanded operations in St. Louis. More: https://lnkd.in/gAFKYH3W BioSTL to 'supercharge' St. Louis neuroscience industry Startup accelerator @BioSTL’s NEURO360 coalition was recently named a finalist in @NSF’s Regional Innovation Engines Program. If chosen, the organization would use the $160M in grant funding to supercharge the region’s neuroscience industry. More: https://lnkd.in/gXGDAt4u